Hyperlipidemia is the one of the major risk factors causing the atherosclerosis of coronary arteries. Treatment of hyperlipidemia with drugs has been confirmed the effcts of therapy showing a decreased incidence of coronary artery disease. Pravastation is one of the new HMG-CoA reductase inhibitors and we studied the long-term hypolipidemic effects and safety of pravastatin in patients with hyperlipidemia and lipid profile after cessation of pravastatin therapy.

We studied 27 patients(6 males and 21 females, range of age : 36~67 years) for 14.7 months whose plasma levels of total cholesterol were higher than 250mg% after one month period of diet therapy. Pravastatin was administered 10mg/day and measured lipid profile at 4 weeks interval, and at 2~3 months after cessation of therapy.

1) Pravastatin significantly reduced the plasma total cholesterol, LDL-cholesterol and triglyceride, but HDL-cholesterol was increased significantly after 12 months pravastatin therapy(p<0.05). 2) Two to three months after the cessation of pravastatin therapy, plasma total cholesterol, LDL-cholesterol and triglyceride were significantly increased(p<0.05), but no significant difference was observed for HDL-cholesterol. 3) The clinical and laboratory examinations before and after pravastatin treatment showed no particular abnormal findings.

These results suggested that long-term pravastatin therapy in patients with hyperlipidemia seems to be very effective and safe. But hyperlipidemia developed again two to three months after the cessation of pravastatin therapy.